Author's response to reviews

Title: Prognostic significance of composite expressions of MCM2, Ki-67 and gelsolin in non-small cell lung cancer

Authors:

Jun Yang (Jun.Yang@RoswellPark.org)
Nithya Ramnath (Nithya.Ramnath@RoswellPark.org)
Kirsten B Moysich (Kirsten.Moysich@RoswellPark.org)
Harold L Asch (asch1@adelphia.net)
Helen Swede (helen.swede@po.state.ct.us)
Sadir J Alrawi (Sadir.Alrawi@RoswellPark.org)
Joel Huberman (Joel.Huberman@RoswellPark.org)
Joseph Geradts (joseph.geradts@duke.edu)
John SJ Brooks (john.brooks@uphs.upenn.edu)
Dongfeng Tan (Dongfeng.Tan@uth.tmc.edu)

Version: 2 Date: 14 April 2006

Author's response to reviews:

April 10, 2006

Dear Editor-in-Chief:

We are delighted to submit the enclosed manuscript entitled "Prognostic significance of composite expressions of MCM2, Ki-67 and gelsolin in non-small cell lung cancer", for consideration as a research paper in BMC Cancer. This research was performed to investigate the composite prognostic significance of MCM2 and Ki-67, two markers of proliferation, and gelsolin, a marker of motility, in non-small cell lung cancer (NSCLC). The novelty of this research lies in the combined analysis of multiple proliferation and motility markers in predicting the clinical outcome of NSCLC. Our results show a clear pattern that higher levels of proliferation and motility are significantly associated with poorer prognosis in NSCLC, which suggests that the composite application of such markers is more valuable than use of a single marker in assessing tumor prognosis. The combinatorial approach utilized in this research may also prove valuable in assessing response to anticancer treatment and the subsequent clinical outcomes in various tumors.

All authors have contributed to the conception, design, analysis, or interpretation of the research. All authors have been involved in the drafting of the manuscript and have approved the final version. No authors have any relationships that could be construed as conflict of interest or financial interests in association with the work presented in this manuscript.

If you should require any further information, please do not hesitate to contact me.

Sincerely,

Jun Yang, M.D., Ph.D.
Department of Epidemiology
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, New York 14263
Phone: (716) 845-8937
Fax: (716) 845-8125; (716) 845-8487
E-mail: Jun.Yang@RoswellPark.org